Open access journal by ESTRO
Joined June 2021
- Tweets62
- Following251
- Followers301
- Likes114
👉 94 patients with isolated local relapse of prostate cancer after definitive irradiation.
👉 Salvage I-125 low-dose-rate brachytherapy was performed in a Comprehensive Cancer Center.
👉 Treatment of whole gland (70%) +- with an MRI-based GTV boost (20%) or focal (10%).
Clinical & Translational Radiation Oncology retweeted
Compliance to MDT recs in OMD pts:
👉83.7% of MDT recommendations correctly implemented
👉Reasons for major deviations: physician decision, patient comorbidity or patient decision.
👉Major deviations associated with more than one distant met and worse OS
doi.org/10.1016/j.ctro.2024.…
Clinical & Translational Radiation Oncology retweeted
A day in the life of an editor in chief... @ctro_journal #radonc
🎆 Now in @ctRO_journal
Impact of Dose, fractionation and motion management on SBRT outcome in adrenal gland tumors. #radonc
👉Nomogram developed by authors predicting outcomes. #radonc
Hot off the press in ctRO by Rogers et al.
🔷 Preoperative Radiosurgery is highly feasible when scheduled the day before neurosurgery.
🔷 The surgical cavity local control rate was equivalent to that reported with postoperative fractionated SRS
ctro.science/article/S2405-6…
#radonc
Also don't miss the accompanying editorial by @cristian_udo @SahgalArjun @HaghighiNeda @drhsoli
ctro.science/article/S2405-6… #radonc
Clinical & Translational Radiation Oncology retweeted
Should preoperative SRS be considered for brain metastases undergoing resection? Great to work with @HaghighiNeda @SahgalArjun @drhsoli on our @ctRO_journal editorial of the PREOP-1 trial. More prospective evidence for this novel paradigm! @Sunnybrook @UofTDRO @PeterMacRadOnc @PeterMacCC @ESTRO_RT @RadiotherapyOn1 #btsm
🔹LDR Brachytherapy for recurrent prostate cancer after definitive radiotherapy
ctro.science/article/S2405-6…
#radonc
🦴 Study on Osteolytic Metastases (SM) Remineralization
🔬 Conclusion: Radiation therapy significantly increases BMD in lytic SM (except renal tumors). No additional benefit of SBRT over cEBRT. Important for surgical decisions in unstable patients.
ctro.science/article/S2405-6…
We are hiring!! We are looking for two associate editors for @ctro_journal! Apply now if you want to be part of a rapidly growing radiotherapy journal by @ESTRO_RT!
ctro.science/content/callfor…
#radonc
Clinical & Translational Radiation Oncology retweeted
And now... updated results of 41 patients CURATIVELY treated with 6m of Dostarlimab (PD-1) WITHOUT ☢️or🔪
✅100% cCR rate
✅0 Local or distance relapses
✅Sustained cCR for > 12 m seen in 20 patients with mFU of 29 m
THIS. IS. AWESOME
#ASCO24
Clinical & Translational Radiation Oncology retweeted
LAURA Trial receives a well deserved huge applause by the audience. Huge benefit in PFS (39 vs 5.6 mo, HR < 0.2. OS still immature and 81% crossover. STAGE III EGFR+ NSCLC INCURABLE? BRAIN RMN BUT NO PET-CT required at baseline. #ASCO24 @LeciaSequist
🌟 Check out these examples showcasing the scope of @ctro_journal! 📝🔬 #radonc
...another fascinating study... ctro.science/article/S2405-6…
